Page 83 - Heart Transplant Protocol

Heart Function Service: Heart Transplant Protocols

mucous membranes. If such contact occurs, wash thoroughly with soap and water, and rinse
eyes thoroughly with plain water

Side effects:
>10%: diarrhea, pyrexia, hypertension, upper respiratory tract infection, vomiting, anemia,
neutropenia, constipation, nausea, and cough
Contraception is advised for during and 30 days after treatment for women of childbearing
potential and for during and 90 days after treatment for men

Reference:

1. Golan DE, Tashjian AH, Armstrong E, Armstrong A. Principles of Pharmacology. 2nd ed. Baltimore, MD:
Lippincott, Williams & Wilkins, 2008:658.
2. Kotton C, Kumar D, Caliendo A, et al. International Consensus guidelines on the Management of
cytomegalovirus in Solid Organ Transplantation. Transplantation 2010;89: 779–795.
3. Pescovitz MD, Ettenger RB, Strife CF, et al. Pharmacokinetics of oral valganciclovir solution and
intravenous ganciclovir in pediatric renal and liver transplant recipients. Transplant Infectious Disease.
2009;1398-2273. (Published Online: Dec 7 2009 )
4. Perrottet N, Laurent A, Decosterd, A, et al. Valganciclovir in Adult Solid Organ Transplant Recipients. Clin
Pharmacokinet. 2009;48:399-418.
5. Product Information: VALCYTE® tablet and oral suspension. Genentech USA, Inc, San Francisco, CA, 2009.
6. Wiltshire H, Hirankaran S, Farrell C, et al. Pharmacokinetic Profile of Ganciclovir After its Oral
Administration and From its prodrug, Valganciclovir, in Solid Organ Transplant Recipients. Clin
Pharmacokinet. 2005;44:495-507.
7. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs oral ganciclovir for prevention
of cytomegalovirus disease in solid organ transplant recipients. Valganciclovir Solid Organ Transplant
Study Group. Am J Transplant. 2004:4;611-20.

Updated November 9, 2017 83